Literature DB >> 3717421

The combined use of clonidine and naltrexone as a rapid, safe, and effective treatment of abrupt withdrawal from methadone.

D S Charney, G R Heninger, H D Kleber.   

Abstract

Combined clonidine and naltrexone treatment allowed 38 of 40 patients addicted to methadone to withdraw completely in 4-5 days. For most patients naltrexone was gradually increased from 1 mg/day to 50 mg/day over 4 days. Clonidine reduced the intensity of naltrexone-induced withdrawal symptoms. Clonidine significantly decreased blood pressure without producing syncope and caused sedation but no other clinical problems. The withdrawal symptoms of anxiety, anorexia, insomnia, restlessness, and muscular aching were most resistant but were mild or nonexistent at discharge. Clonidine-naltrexone treatment should succeed with patients receiving methadone doses up to 50 mg/day, facilitate naltrexone maintenance, and apply to many clinical settings.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3717421     DOI: 10.1176/ajp.143.7.831

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  10 in total

1.  Ambulatory opiate detoxification and primary care: a role for the primary care physician.

Authors:  P G O'Connor; M E Waugh; R S Schottenfeld; I A Diakogiannis; B J Rounsaville
Journal:  J Gen Intern Med       Date:  1992 Sep-Oct       Impact factor: 5.128

2.  Manitoba's methadone program: the first 15 years.

Authors:  N el-Guebaly; J O'Riordan
Journal:  CMAJ       Date:  1988-03-01       Impact factor: 8.262

Review 3.  Methadone maintenance in the treatment of opioid dependence. A current perspective.

Authors:  J E Zweben; J T Payte
Journal:  West J Med       Date:  1990-05

4.  Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.

Authors:  Maria Sullivan; Adam Bisaga; Martina Pavlicova; C Jean Choi; Kaitlyn Mishlen; Kenneth M Carpenter; Frances R Levin; Elias Dakwar; John J Mariani; Edward V Nunes
Journal:  Am J Psychiatry       Date:  2017-01-10       Impact factor: 18.112

5.  Nucleus accumbens as a substrate for the aversive stimulus effects of opiate withdrawal.

Authors:  G F Koob; T L Wall; F E Bloom
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

6.  Management of chronic headache.

Authors:  R Smith
Journal:  Can Fam Physician       Date:  1989-09       Impact factor: 3.275

7.  Primary care-based ambulatory opioid detoxification: the results of a clinical trial.

Authors:  P G O'Connor; M E Waugh; K M Carroll; B J Rounsaville; I A Diagkogiannis; R S Schottenfeld
Journal:  J Gen Intern Med       Date:  1995-05       Impact factor: 5.128

8.  Opioid peptides and primary biliary cirrhosis.

Authors:  J R Thornton; M S Losowsky
Journal:  BMJ       Date:  1988-12-10

Review 9.  Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies.

Authors:  Adam Bisaga; Paolo Mannelli; Maria A Sullivan; Suzanne K Vosburg; Peggy Compton; George E Woody; Thomas R Kosten
Journal:  Am J Addict       Date:  2018-04

Review 10.  Pharmacologic treatments for opioid dependence: detoxification and maintenance options.

Authors:  Herbert D Kleber
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.